STEAP2 and prostate cancer: We confirmed literature reports of STEAP2 overexpression in prostate cancer by using large-scale genomics screening in the QIAGEN Omicssoft OncoLand database, where prostate adenocarcinoma and normal prostate tissue displayed substantially higher gene expression levels than all other tumor types and normal tissues profiled (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI169655DS1).